Stock Events

Medigene 

€1.25
12
-€0.01-0.8% Today

Statistics

Day High
1.25
Day Low
1.21
52W High
-
52W Low
-
Volume
24,288
Avg. Volume
-
Mkt Cap
36.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15AugExpected
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Next
-0.95
-0.9
-0.86
-0.81
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MDG1.XETRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.
Show more...
CEO
Dr. Selwyn Ho MB BS, MBBS
Employees
76
Country
DE
ISIN
DE000A1X3W00
WKN
000A1X3W0

Listings